Our group is actively engaged in addressing physicochemical property issues in drug development. We do screening of salts, cocrystals, polymorphs of new chemical entities (NCEs), and active pharmaceutical ingredients (APIs). We have developed several novel solid forms of Dabrafenib, Pazopanib, and a new polymorph of Hydroxyurea. We are also interested in developing single-phase stoichiometric fixed-dose combinations (FDCs) to address issues of drug combination therapy and patient compliance. Recently we have developed Dabrafenib-Panobinostat and Pazopanib-Fenamic acid FDCs.

We specialize in structure-based drug designing to address the solubility, permeability, and bioefficacy of existing drug molecules. Virtual screening of potential molecules by replacing atoms, functional groups, or fragments of approved drugs is done through computer-added drug designing (CADD). Subsequently, hit molecules are explored by synthesizing analogs followed by cell-line analysis. We are also working on the new drug design on the pyridone scaffold.